A Road Map for Remote Digital Health Technology for Motor Neuron Disease.

Despite recent and potent technological advances, the real-world implementation of remote digital health technology in the care and monitoring of patients with motor neuron disease has not yet been realized. Digital health technology may increase the accessibility to and personalization of care, whereas remote biosensors could optimize the collection of vital clinical parameters, irrespective of patients' ability to visit the clinic. To facilitate the wide-scale adoption of digital health care technology and to align current initiatives, we outline a road map that will identify clinically relevant digital parameters; mediate the development of benefit-to-burden criteria for innovative technology; and direct the validation, harmonization, and adoption of digital health care technology in real-world settings. We define two key end products of the road map: (1) a set of reliable digital parameters to capture data collected under free-living conditions that reflect patient-centric measures and facilitate clinical decision making and (2) an integrated, open-source system that provides personalized feedback to patients, health care providers, clinical researchers, and caregivers and is linked to a flexible and adaptable platform that integrates patient data in real time. Given the ever-changing care needs of patients and the relentless progression rate of motor neuron disease, the adoption of digital health care technology will significantly benefit the delivery of care and accelerate the development of effective treatments.

[1]  S. Paganoni,et al.  Telemedicine to innovate amyotrophic lateral sclerosis multidisciplinary care: The time has come , 2019, Muscle & nerve.

[2]  S. Steinhubl,et al.  Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial , 2018, JAMA.

[3]  R. Chiaramonte,et al.  Acoustic analysis of voice in bulbar amyotrophic lateral sclerosis: a systematic review and meta-analysis of studies , 2019, Logopedics, phoniatrics, vocology.

[4]  A. Al-Chalabi,et al.  Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  Max A. Little,et al.  Technology in Parkinson's disease: Challenges and opportunities , 2016, Movement disorders : official journal of the Movement Disorder Society.

[6]  A. Moser,et al.  Series: Practical guidance to qualitative research. Part 3: Sampling, data collection and analysis , 2017, The European journal of general practice.

[7]  Jennifer C. Goldsack,et al.  Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review , 2018, Digital Biomarkers.

[8]  Using technology to improve access to specialist care in amyotrophic lateral sclerosis: A systematic review , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[9]  L. H. van den Berg,et al.  Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials , 2019, Neurology.

[10]  L. H. van den Berg,et al.  Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  S. Mawson,et al.  The TiM system: developing a novel telehealth service to improve access to specialist care in motor neurone disease using user-centered design , 2018, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[12]  P. Kothare,et al.  Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality , 2018, Clinical pharmacology and therapeutics.

[13]  A. Al-Chalabi,et al.  A proposed staging system for amyotrophic lateral sclerosis , 2012, Brain : a journal of neurology.

[14]  A. Al-Chalabi,et al.  Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study , 2019, JMIR mHealth and uHealth.

[15]  Stephanie H. Felgoise,et al.  A Qualitative Study of Multidisciplinary ALS Clinic Use in the United States , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[16]  S. Mawson,et al.  Process evaluation and exploration of telehealth in motor neuron disease in a UK specialist centre , 2019, BMJ Open.

[17]  R. Henderson,et al.  Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach , 2017, Journal of multidisciplinary healthcare.

[18]  O. Hardiman,et al.  Needs of informal caregivers across the caregiving course in amyotrophic lateral sclerosis: a qualitative analysis , 2018, BMJ Open.

[19]  B. Bloem,et al.  The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. , 2020, JAMA neurology.

[20]  O. Hardiman,et al.  A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  L. H. van den Berg,et al.  Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study , 2019, Journal of Neurology.

[22]  O. Hardiman,et al.  Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial , 2013, The Lancet Neurology.

[23]  A. Al-Chalabi,et al.  TRICALS: creating a highway toward a cure , 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[24]  S. Paganoni,et al.  Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities , 2020, Muscle & nerve.

[25]  Esther T Kruitwagen,et al.  The current use of telehealth in ALS care and the barriers to and facilitators of implementation: a systematic review , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[26]  A. Chiò,et al.  Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  Esther T Kruitwagen,et al.  Telehealth as part of specialized ALS care: feasibility and user experiences with “ALS home-monitoring and coaching” , 2020, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[28]  M. Gagnon,et al.  Some Multidimensional Unintended Consequences of Telehealth Utilization: A Multi-Project Evaluation Synthesis , 2019, International journal of health policy and management.

[29]  Ioannis Tarnanas,et al.  Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials , 2018, Alzheimer's & dementia.

[30]  S. Mawson,et al.  Using telehealth in motor neuron disease to increase access to specialist multidisciplinary care: a UK-based pilot and feasibility study , 2019, BMJ Open.

[31]  ANNETTE DE VITO DABBS,et al.  User-Centered Design and Interactive Health Technologies for Patients , 2009, Computers, informatics, nursing : CIN.

[32]  A. Al-Chalabi,et al.  ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS , 2018, Neurology.

[33]  Visar Berisha,et al.  ALS longitudinal studies with frequent data collection at home: study design and baseline data , 2018, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[34]  Karel G M Moons,et al.  Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model , 2018, The Lancet Neurology.

[35]  A. Chiò,et al.  ALS clinical trials , 2011, Neurology.

[36]  Paolo Bonato,et al.  A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies , 2019, Movement disorders : official journal of the Movement Disorder Society.

[37]  Visar Berisha,et al.  Improved ALS clinical trials through frequent at‐home self‐assessment: a proof of concept study , 2020, Annals of clinical and translational neurology.

[38]  S. Edland,et al.  Power calculations for clinical trials in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[39]  T. Hortobágyi,et al.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.